Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

MLA

Chia-Chi Lin, et al. “Outcomes in Patients with Non-Small-Cell Lung Cancer and Acquired Thr790Met Mutation Treated with Osimertinib: A Genomic Study.” The Lancet Respiratory Medicine, vol. 6, Feb. 2018, pp. 107–16. EBSCOhost, https://doi.org/10.1016/s2213-2600(17)30480-0.

APA

Chia-Chi Lin, Jin-Yuan Shih, Tzu-Hsiu Tsai, Min-Shu Hsieh, Kenneth S. Thress, Derek De-Rui Huang, Kang-Yi Su, Jih-Hsing Lee, Ya-Ying Bai, James Chih-Hsin Yang, Wei-Yu Liao, Chong-Jen Yu, Chao-Chi Ho, & Yih-Leong Chang. (2018). Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. The Lancet Respiratory Medicine, 6, 107–116. https://doi.org/10.1016/s2213-2600(17)30480-0

Chicago

Chia-Chi Lin, Jin-Yuan Shih, Tzu-Hsiu Tsai, Min-Shu Hsieh, Kenneth S. Thress, Derek De-Rui Huang, Kang-Yi Su, et al. 2018. “Outcomes in Patients with Non-Small-Cell Lung Cancer and Acquired Thr790Met Mutation Treated with Osimertinib: A Genomic Study.” The Lancet Respiratory Medicine 6 (February): 107–16. doi:10.1016/s2213-2600(17)30480-0.